{"id":"tev-48125","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting Nav1.5, TEV-48125 is expected to reduce the abnormal electrical activity in the heart that can lead to atrial fibrillation. This mechanism of action is thought to be responsible for the therapeutic effects of TEV-48125 in treating atrial fibrillation.","oneSentence":"TEV-48125 is a selective, reversible inhibitor of the sodium-activated potassium channel Nav1.5.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:20.300Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT05458011","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2022-09-30","conditions":"Migraine","enrollment":365},{"nctId":"NCT03539393","phase":"","title":"Fremanezumab Compassionate Use Program for Pediatric Patients","status":"AVAILABLE","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"","conditions":"Migraine","enrollment":""},{"nctId":"NCT04041284","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2019-09-13","conditions":"Migraine, Major Depressive Disorder","enrollment":353},{"nctId":"NCT03303105","phase":"PHASE3","title":"Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2017-12-07","conditions":"Migraine","enrollment":50},{"nctId":"NCT03347188","phase":"PHASE2","title":"A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2017-12-18","conditions":"Post-Traumatic Headache","enrollment":87},{"nctId":"NCT02673567","phase":"PHASE1","title":"To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2016-03-31","conditions":"Pharmacokinetics","enrollment":64},{"nctId":"NCT02621931","phase":"PHASE3","title":"Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2016-03-22","conditions":"Migraine","enrollment":1130},{"nctId":"NCT03308968","phase":"PHASE3","title":"An Efficacy and Safety Study of Fremanezumab in Adults With Migraine","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2017-10-13","conditions":"Migraine Prophylaxis","enrollment":838},{"nctId":"NCT02629861","phase":"PHASE3","title":"Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2016-03-23","conditions":"Migraine","enrollment":875},{"nctId":"NCT02964338","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2017-01-17","conditions":"Chronic Cluster Headache","enrollment":259},{"nctId":"NCT03107052","phase":"PHASE3","title":"A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2017-04-27","conditions":"Cluster Headache","enrollment":275},{"nctId":"NCT02945046","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2017-01-19","conditions":"Episodic Cluster Headache","enrollment":169},{"nctId":"NCT02638103","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2016-02-26","conditions":"Migraine","enrollment":1890},{"nctId":"NCT04355117","phase":"PHASE3","title":"A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2020-06-17","conditions":"Migraine","enrollment":71},{"nctId":"NCT03303092","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2017-12-19","conditions":"Migraine","enrollment":357},{"nctId":"NCT03303079","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2017-12-19","conditions":"Migraine","enrollment":571}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TEV-48125","genericName":"TEV-48125","companyName":"Otsuka Pharmaceutical Co., Ltd.","companyId":"otsuka-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TEV-48125 is a selective, reversible inhibitor of the sodium-activated potassium channel Nav1.5. Used for Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}